Kestra Advisory Services LLC cut its position in Sanofi (NASDAQ:SNY – Get Rating) by 33.7% in the third quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm owned 30,114 shares of the company’s stock after selling 15,278 shares during the quarter. Kestra Advisory Services LLC’s holdings in Sanofi were worth $1,145,000 at the end of the most recent quarter.
A number of other hedge funds have also recently added to or reduced their stakes in the company. FMR LLC increased its stake in Sanofi by 1.3% in the second quarter. FMR LLC now owns 18,715,053 shares of the company’s stock valued at $936,314,000 after purchasing an additional 234,158 shares during the period. Price T Rowe Associates Inc. MD increased its position in Sanofi by 162.9% in the 2nd quarter. Price T Rowe Associates Inc. MD now owns 17,244,354 shares of the company’s stock valued at $862,735,000 after acquiring an additional 10,684,509 shares during the period. Invesco Ltd. raised its stake in Sanofi by 2.3% during the 1st quarter. Invesco Ltd. now owns 5,077,848 shares of the company’s stock valued at $260,697,000 after acquiring an additional 112,404 shares during the last quarter. Arrowstreet Capital Limited Partnership lifted its position in Sanofi by 276.1% during the 1st quarter. Arrowstreet Capital Limited Partnership now owns 3,362,112 shares of the company’s stock worth $172,611,000 after acquiring an additional 2,468,271 shares during the period. Finally, Lazard Asset Management LLC grew its stake in shares of Sanofi by 0.8% in the 1st quarter. Lazard Asset Management LLC now owns 3,321,721 shares of the company’s stock valued at $170,536,000 after purchasing an additional 25,457 shares during the last quarter. Hedge funds and other institutional investors own 10.04% of the company’s stock.
Sanofi Stock Performance
SNY opened at $48.53 on Wednesday. Sanofi has a 1-year low of $36.91 and a 1-year high of $58.10. The stock has a market cap of $123.02 billion, a P/E ratio of 17.58, a P/E/G ratio of 1.15 and a beta of 0.56. The stock’s 50 day simple moving average is $47.23 and its 200 day simple moving average is $42.73. The company has a debt-to-equity ratio of 0.22, a current ratio of 1.29 and a quick ratio of 0.34.
Analyst Ratings Changes
Several equities research analysts have recently commented on the company. The Goldman Sachs Group initiated coverage on Sanofi in a research note on Friday, December 16th. They set a “buy” rating for the company. Morgan Stanley reaffirmed an “overweight” rating on shares of Sanofi in a report on Tuesday, December 13th. StockNews.com initiated coverage on shares of Sanofi in a report on Wednesday, October 12th. They set a “strong-buy” rating for the company. Barclays lowered their price objective on Sanofi from €105.00 ($114.13) to €85.00 ($92.39) and set an “equal weight” rating on the stock in a report on Friday, October 14th. Finally, TheStreet raised Sanofi from a “c+” rating to a “b-” rating in a research note on Friday, December 2nd. Five investment analysts have rated the stock with a hold rating, six have assigned a buy rating and one has issued a strong buy rating to the company. According to MarketBeat, the company presently has a consensus rating of “Moderate Buy” and a consensus price target of $102.88.
Sanofi, together with its subsidiaries, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, and internationally. It operates through three segments: Pharmaceuticals, Vaccines, and Consumer Healthcare. The company provides specialty care products, including human monoclonal antibodies; products for multiple sclerosis, neurology, other inflammatory diseases, immunology, rare diseases, oncology, and rare blood disorders; medicines for diabetes; and cardiovascular and established prescription products.
- Get a free copy of the StockNews.com research report on Sanofi (SNY)
- Pliant Therapeutics Gaps 34% Higher: More Upside To Come?
- How Will Early 2023 Layoffs Affect These 5 Biotech Stocks?
- Is the Pain Over for Baudax Bio Investors after a 70% Spike?
- Will Rocket Lab’s First U.S. Launch Send Stock Into Stratosphere?
- 3 Retail Stocks Ringing the Register in 2023
Receive News & Ratings for Sanofi Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sanofi and related companies with MarketBeat.com's FREE daily email newsletter.